CRANBURY, N.J.--(BUSINESS WIRE)--July 6, 2006--Valera Pharmaceuticals, Inc. announced it submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for SUPPRELIN®-LA, a 12-month implant for central precocious puberty (CPP), or the early onset of puberty in children.
